{"transactions":[{"id":2350313,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-04T16:21:53.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The total number of options vest in equal parts on July 31, 2022 and December 31, 2022, such that 100% of the options will be fully vested and exercisable on December 31, 2022."}],"balance_after":275000,"derivative":{"exercise_price":1.99,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001601485-22-000013","document":"wf-form4_164642889806390.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000160148522000013/wf-form4_164642889806390.xml","form_type":"4"}},{"id":2350312,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-04T16:21:53.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the \"Vesting Commencement Date\"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":175000,"derivative":{"exercise_price":1.99,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001601485-22-000013","document":"wf-form4_164642889806390.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000160148522000013/wf-form4_164642889806390.xml","form_type":"4"}},{"id":2462436,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-12-21T16:25:24.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":358,"price":2.6201,"value":937.9958,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted on March 18, 2021 by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards (\"RSAs\") granted by the Issuer."}],"balance_after":35136,"source":{"system":"sec-edgar","filing":"0001601485-21-000091","document":"wf-form4_164012191372345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000160148521000091/wf-form4_164012191372345.xml","form_type":"4"}},{"id":2500779,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-11-22T19:09:11.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":374,"price":4.13,"value":1544.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted on March 18, 2021 by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards (\"RSAs\") granted by the Issuer."}],"balance_after":35494,"source":{"system":"sec-edgar","filing":"0001601485-21-000077","document":"wf-form4_163762613730453.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000160148521000077/wf-form4_163762613730453.xml","form_type":"4"}},{"id":2538176,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-20T17:06:44.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":373,"price":8.62,"value":3215.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards (\"RSAs\") granted by the Issuer."}],"balance_after":35868,"source":{"system":"sec-edgar","filing":"0001601485-21-000062","document":"wf-form4_163476398271611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000160148521000062/wf-form4_163476398271611.xml","form_type":"4"}},{"id":2563071,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-21T16:32:03.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":376,"price":10.07,"value":3786.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards (\"RSAs\") granted by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.07 to $10.09 inclusive."}],"balance_after":36241,"source":{"system":"sec-edgar","filing":"0001601485-21-000058","document":"wf-form4_163225630889400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000160148521000058/wf-form4_163225630889400.xml","form_type":"4"}},{"id":2596194,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-19T16:06:19.000Z","date":"2021-08-18","kind":"sale","acquired":false,"shares":381,"price":9.03,"value":3440.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards (\"RSAs\") granted by the Issuer."}],"balance_after":36617,"source":{"system":"sec-edgar","filing":"0001601485-21-000052","document":"wf-form4_162940355890439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000160148521000052/wf-form4_162940355890439.xml","form_type":"4"}},{"id":2627161,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-07-22T18:04:05.000Z","date":"2021-07-21","kind":"sale","acquired":false,"shares":365,"price":10.98,"value":4007.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards (\"RSAs\") granted by the Issuer."}],"balance_after":36998,"source":{"system":"sec-edgar","filing":"0001601485-21-000038","document":"wf-form4_162699140642124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000160148521000038/wf-form4_162699140642124.xml","form_type":"4"}},{"id":2660988,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-06-21T16:05:41.000Z","date":"2021-06-18","kind":"sale","acquired":false,"shares":366,"price":13.2,"value":4831.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards (\"RSAs\") granted by the Issuer."}],"balance_after":37363,"source":{"system":"sec-edgar","filing":"0001601485-21-000029","document":"wf-form4_162430591954382.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000160148521000029/wf-form4_162430591954382.xml","form_type":"4"}},{"id":2705509,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-05-19T17:10:44.000Z","date":"2021-05-18","kind":"sale","acquired":false,"shares":363,"price":13.91,"value":5049.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards (\"RSAs\") granted by the Issuer."}],"balance_after":37729,"source":{"system":"sec-edgar","filing":"0001601485-21-000025","document":"wf-form4_162145860149330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000160148521000025/wf-form4_162145860149330.xml","form_type":"4"}},{"id":2743980,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-04-20T17:19:56.000Z","date":"2021-04-19","kind":"sale","acquired":false,"shares":381,"price":13.55,"value":5162.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of shares of Restricted Stock of the Issuer."}],"balance_after":38092,"source":{"system":"sec-edgar","filing":"0001601485-21-000013","document":"wf-form4_161895358056958.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000160148521000013/wf-form4_161895358056958.xml","form_type":"4"}},{"id":2777605,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-03-19T16:06:46.000Z","date":"2021-03-17","kind":"sale","acquired":false,"shares":442,"price":19.13,"value":8455.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold to the Issuer solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a Restricted Stock Awards (\"RSAs\") of the Issuer."}],"balance_after":38453,"source":{"system":"sec-edgar","filing":"0001567619-21-006685","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000156761921006685/doc1.xml","form_type":"4"}},{"id":2874485,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-08T12:59:19.000Z","date":"2021-02-04","kind":"grant","acquired":true,"shares":70012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2021 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":70012,"derivative":{"exercise_price":16,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":70012},"source":{"system":"sec-edgar","filing":"0001567619-21-002413","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640447/000156761921002413/doc1.xml","form_type":"4"}},{"id":3732996,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2018-12-13T16:33:11.000Z","date":"2018-12-12","kind":"disposition_to_issuer","acquired":false,"shares":772500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":772500},"source":{"system":"sec-edgar","filing":"0000899243-18-030881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924318030881/doc4.xml","form_type":"4"}},{"id":3732995,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-12-13T16:33:11.000Z","date":"2018-12-12","kind":"disposition_to_issuer","acquired":false,"shares":148279,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. (\"Keryx\"), Akebia Therapeutics, Inc. (\"Akebia\") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the \"Merger Agreement\"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the \"Exchange Ratio\"), with fractional shares being paid in cash as provided in the Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 66,039 shares of restricted stock, the vesting of which was accelerated as a result of a termination of the reporting person's employment in connection with the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. (\"Keryx\"), Akebia Therapeutics, Inc. (\"Akebia\") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the \"Merger Agreement\"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the \"Exchange Ratio\"), with fractional shares being paid in cash as provided in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 66,039 shares of restricted stock, the vesting of which was accelerated as a result of a termination of the reporting person's employment in connection with the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-030881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924318030881/doc4.xml","form_type":"4"}},{"id":3761932,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-11-16T08:49:51.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":1156,"price":2.77,"value":3202.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of a total of 1,156 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,063 shares of restricted stock on November 14, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 66,039 shares of restricted stock."}],"balance_after":148279,"source":{"system":"sec-edgar","filing":"0001114220-18-000110","document":"wf-form4_154237617523458.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000110/wf-form4_154237617523458.xml","form_type":"4"}},{"id":3780753,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-10-30T16:07:47.000Z","date":"2018-10-29","kind":"sale","acquired":false,"shares":1253,"price":3.07,"value":3846.71,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of a total of 1,253 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on October 28, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 70,102 shares of restricted stock."}],"balance_after":149435,"source":{"system":"sec-edgar","filing":"0001114220-18-000100","document":"wf-form4_154093005033411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000100/wf-form4_154093005033411.xml","form_type":"4"}},{"id":3842329,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-08-16T07:10:50.000Z","date":"2018-08-15","kind":"sale","acquired":false,"shares":1186,"price":3.04,"value":3605.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of a total of 1,186 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,063 shares of restricted stock on August 14, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 74,581 shares of restricted stock."}],"balance_after":150688,"source":{"system":"sec-edgar","filing":"0001114220-18-000093","document":"wf-form4_153441783359781.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000093/wf-form4_153441783359781.xml","form_type":"4"}},{"id":3858171,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-07-31T16:34:41.000Z","date":"2018-07-30","kind":"sale","acquired":false,"shares":1282,"price":3.86,"value":4948.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of a total of 1,282 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on July 28, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 78,644 shares of restricted stock."}],"balance_after":151874,"source":{"system":"sec-edgar","filing":"0001114220-18-000086","document":"wf-form4_153306926524689.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000086/wf-form4_153306926524689.xml","form_type":"4"}},{"id":3931412,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-05-16T16:40:27.000Z","date":"2018-05-15","kind":"sale","acquired":false,"shares":1158,"price":5.69,"value":6589.02,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,158 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,063 shares of restricted stock on May 14, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 83,123 shares of restricted stock."}],"balance_after":153156,"source":{"system":"sec-edgar","filing":"0001114220-18-000055","document":"wf-form4_152650321264174.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000055/wf-form4_152650321264174.xml","form_type":"4"}},{"id":3952430,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-05-01T16:14:30.000Z","date":"2018-04-30","kind":"sale","acquired":false,"shares":1311,"price":4.67,"value":6122.37,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,311 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on April 27, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 87,186 shares of restricted stock."}],"balance_after":154314,"source":{"system":"sec-edgar","filing":"0001114220-18-000046","document":"wf-form4_152520565539406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000046/wf-form4_152520565539406.xml","form_type":"4"}},{"id":3958159,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-04-24T16:29:10.000Z","date":"2018-04-23","kind":"sale","acquired":false,"shares":1111,"price":4.59,"value":5099.49,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,111 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 3,749 shares of restricted stock on April 20, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 91,665 shares of restricted stock."}],"balance_after":155625,"source":{"system":"sec-edgar","filing":"0001114220-18-000041","document":"wf-form4_152460173663254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000041/wf-form4_152460173663254.xml","form_type":"4"}},{"id":3985562,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (right to buy)","published_at":"2018-03-22T17:30:35.000Z","date":"2018-03-20","kind":"grant","acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest according to the following schedule: one-third of the 82,500 options will vest on March 20, 2019 and one-twelfth will vest on each of June 20, 2019, September 20, 2019, December 20, 2019, March 20, 2020, June 20, 2020, September 20, 2020, December 20, 2020 and March 20, 2021."}],"balance_after":82500,"derivative":{"exercise_price":4.16,"exercise_date":"2019-03-20","expiration_date":"2028-03-20","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001114220-18-000034","document":"wf-form4_152175422140887.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000034/wf-form4_152175422140887.xml","form_type":"4"}},{"id":3985561,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-03-22T17:30:35.000Z","date":"2018-03-20","kind":"grant","acquired":true,"shares":41250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The 41,250 shares are restricted common stock, with one-third of the 41,250 shares vesting on March 20, 2019 and one-twelfth vesting on each of June 20, 2019, September 20, 2019, December 20, 2019, March 20, 2020, June 20, 2020, September 20, 2020, December 20, 2020 and March 20, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The 41,250 shares are restricted common stock, with one-third of the 41,250 shares vesting on March 20, 2019 and one-twelfth vesting on each of June 20, 2019, September 20, 2019, December 20, 2019, March 20, 2020, June 20, 2020, September 20, 2020, December 20, 2020 and March 20, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 95,414 shares of restricted stock."}],"balance_after":156736,"source":{"system":"sec-edgar","filing":"0001114220-18-000034","document":"wf-form4_152175422140887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000034/wf-form4_152175422140887.xml","form_type":"4"}},{"id":4052856,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-02-16T16:04:28.000Z","date":"2018-02-15","kind":"sale","acquired":false,"shares":5652,"price":4.81,"value":27186.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 5,652 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 16,251 shares of restricted stock on February 14, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 54,164 shares of restricted stock."}],"balance_after":115486,"source":{"system":"sec-edgar","filing":"0001114220-18-000022","document":"wf-form4_151881505408745.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000022/wf-form4_151881505408745.xml","form_type":"4"}},{"id":4083832,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-01-31T17:19:10.000Z","date":"2018-01-29","kind":"sale","acquired":false,"shares":1541,"price":4.81,"value":7412.21,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,541 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on January 26, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 70,415 shares of restricted stock."}],"balance_after":121138,"source":{"system":"sec-edgar","filing":"0001114220-18-000014","document":"wf-form4_151743713508590.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000014/wf-form4_151743713508590.xml","form_type":"4"}},{"id":4091327,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-01-24T16:16:34.000Z","date":"2018-01-23","kind":"sale","acquired":false,"shares":1322,"price":4.92,"value":6504.24,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,322 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 3,749 shares of restricted stock on January 22, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 74,894 shares of restricted stock."}],"balance_after":122679,"source":{"system":"sec-edgar","filing":"0001114220-18-000008","document":"wf-form4_151682858026825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422018000008/wf-form4_151682858026825.xml","form_type":"4"}},{"id":4177787,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-10-31T16:12:16.000Z","date":"2017-10-30","kind":"sale","acquired":false,"shares":1405,"price":6.03,"value":8472.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,405 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on October 27, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 78,643 shares of restricted stock."}],"balance_after":124001,"source":{"system":"sec-edgar","filing":"0001114220-17-000042","document":"wf-form4_150948072238816.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422017000042/wf-form4_150948072238816.xml","form_type":"4"}},{"id":4181431,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-10-24T16:21:13.000Z","date":"2017-10-23","kind":"sale","acquired":false,"shares":1179,"price":6.53,"value":7698.87,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,179 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 3,749 shares of restricted stock on October 20, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 83,122 shares of restricted stock."}],"balance_after":125406,"source":{"system":"sec-edgar","filing":"0001114220-17-000034","document":"wf-form4_150887645896227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422017000034/wf-form4_150887645896227.xml","form_type":"4"}},{"id":4247618,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-08-01T16:25:48.000Z","date":"2017-07-31","kind":"sale","acquired":false,"shares":1445,"price":7.14,"value":10317.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,445 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on July 28, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 86,871 shares of restricted stock."}],"balance_after":126585,"source":{"system":"sec-edgar","filing":"0001114220-17-000020","document":"wf-form4_150161913493860.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422017000020/wf-form4_150161913493860.xml","form_type":"4"}},{"id":4252108,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-07-25T17:00:21.000Z","date":"2017-07-24","kind":"sale","acquired":false,"shares":1214,"price":7.27,"value":8825.78,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,214 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 3,750 shares of restricted stock on July 21, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 91,350 shares of restricted stock."}],"balance_after":128030,"source":{"system":"sec-edgar","filing":"0001114220-17-000013","document":"wf-form4_150101640651405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000111422017000013/wf-form4_150101640651405.xml","form_type":"4"}},{"id":4335886,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-05-03T16:05:27.000Z","date":"2017-05-01","kind":"sale","acquired":false,"shares":1441,"price":5.97,"value":8602.77,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,441 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,480 shares of restricted stock on April 28, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 95,100 shares of restricted stock."}],"balance_after":129244,"source":{"system":"sec-edgar","filing":"0000899243-17-011612","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924317011612/doc4.xml","form_type":"4"}},{"id":4344784,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-04-26T16:05:34.000Z","date":"2017-04-24","kind":"sale","acquired":false,"shares":1209,"price":5.73,"value":6927.57,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,209 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 3,750 shares of restricted stock on April 21, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 99,580 shares of restricted stock."}],"balance_after":130685,"source":{"system":"sec-edgar","filing":"0000899243-17-010904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924317010904/doc4.xml","form_type":"4"}},{"id":4384874,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-03-15T18:31:09.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":97500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest according to the following schedule: one-third of the 97,500 options will vest on February 14, 2018 and one-twelfth will vest on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020."}],"balance_after":97500,"derivative":{"exercise_price":5.53,"exercise_date":"2018-02-14","expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":97500},"source":{"system":"sec-edgar","filing":"0000899243-17-007648","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924317007648/doc4.xml","form_type":"4"}},{"id":4384873,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-03-15T18:31:09.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":48750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The 48,750 shares are restricted common stock, with one-third of the 48,750 shares vesting on February 14, 2018 and one-twelfth vesting on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The 48,750 shares are restricted common stock, with one-third of the 48,750 shares vesting on February 14, 2018 and one-twelfth vesting on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 103,330 shares of restricted stock."}],"balance_after":131894,"source":{"system":"sec-edgar","filing":"0000899243-17-007648","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924317007648/doc4.xml","form_type":"4"}},{"id":4475861,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-01-31T16:05:41.000Z","date":"2017-01-30","kind":"sale","acquired":false,"shares":6984,"price":4.65,"value":32475.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 6,984 shares of common stock was made in order to satisfy Dr. Neylan's income tax withholding obligation upon the vesting of 17,917 shares of restricted stock on January 27, 2017. Dr. Neylan had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 54,583 shares of restricted stock."}],"balance_after":83144,"source":{"system":"sec-edgar","filing":"0000899243-17-002275","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924317002275/doc4.xml","form_type":"4"}},{"id":4482121,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-01-25T16:06:13.000Z","date":"2017-01-23","kind":"sale","acquired":false,"shares":1428,"price":5.39,"value":7696.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,428 shares of common stock was made in order to satisfy Dr. Neylan's income tax withholding obligation upon the vesting of 3,750 shares of restricted stock on January 22, 2017. Dr. Neylan had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 72,500 shares of restricted stock."}],"balance_after":90128,"source":{"system":"sec-edgar","filing":"0000899243-17-001941","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924317001941/doc4.xml","form_type":"4"}},{"id":4575123,"issuer":{"id":161794,"kind":"organization","name":"KERYX BIOPHARMACEUTICALS INC","symbol":"KERX"},"owners":[{"id":129509,"kind":"person","name":"Neylan John F.","position":1,"cik":"0001640447","reported_name":"Neylan John F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-10-25T16:05:30.000Z","date":"2016-10-24","kind":"sale","acquired":false,"shares":1211,"price":4.72,"value":5715.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Sale of a total of 1,211 shares of common stock was made in order to satisfy Dr. Neylan's income tax withholding obligation upon the vesting of 3,750 shares of restricted stock on October 22, 2016. Dr. Neylan had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 76,250 shares of restricted stock."}],"balance_after":91556,"source":{"system":"sec-edgar","filing":"0000899243-16-032270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114220/000089924316032270/doc4.xml","form_type":"4"}}]}